Mesothelioma radiotherapy side effect study (MESORTIBO)
Part of Cancer, Lungs & breathing clinical trials.
This study looks for markers in the blood that can predict side effects in patients with pleural mesothelioma who receive high-dose radiation. If you've had chemotherapy and are getting or have gotten high-dose radiation to the whole chest, researchers want to see if they can identify who is at higher risk of side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with malignant pleural mesothelioma (a rare cancer of the lung lining)
- You have already had chemotherapy
- You have had non-curative surgery (such as a diagnostic scope or a partial removal)
- You are getting, or have already gotten, high-dose radiation to the whole chest (50 gray with possible extra boost to certain areas)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
This early-stage trial tests whether RD133 can be safe and effective for people whose solid tumors have a high “mesothelin” marker and that have not responded to at least two standard treatments. If you qualify, you’ll be checked closely for side effects and whether the tumor responds.
This study follows people with cancer to better understand which treatments cause certain side effects when radiation is combined with targeted (molecular) medicines. Your participation may help doctors predict and manage side effects more safely in the future.
This study tests proton beam radiation aimed at one side of the chest in people with malignant pleural mesothelioma who are not yet having chemotherapy. The goal is to control the cancer while preserving breathing and quality of life for the right patients.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
Hear when a new Pleural Mesothelioma Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.